TRAW

SEC source: 0001203603-25-000005 · form4-10162025_121008.xml · derivative · entry 1

STOVER JACK E · CIK 0001203603 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,530

Underlying: Common Stock · 11,530 shares

Expires 2035-10-12

F1 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date.

SEC source: 0001958857-25-000006 · form4-10162025_121057.xml · derivative · entry 1

Clarke Trafford · CIK 0001958857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,530

Underlying: Common Stock · 11,530 shares

Expires 2035-10-12

F1 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date.

SEC source: 0001813552-25-000004 · form4-10162025_121000.xml · derivative · entry 1

Shoemaker Mary Teresa · CIK 0001813552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,530

Underlying: Common Stock · 11,530 shares

Expires 2035-10-12

F1 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date.

SEC source: 0002125562-26-000004 · form4-04082026_060446.xml · derivative · entry 2

Parker Charles Nolan · CIK 0002125562 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,406

Underlying: Common Stock · 32,406 shares

Expires 2035-10-12

F2 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0001586657-25-000005 · form4-10142025_111013.xml · derivative · entry 1

Leaman John Harold · CIK 0001586657 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,609

Underlying: Common Stock · 15,609 shares

Expires 2035-10-01

F1 · derivative.exercise_date: These options vest over three years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.

SEC source: 0001415889-25-017997 · form4-06232025_090659.xml · derivative · entry 1

Clarke Trafford · CIK 0001958857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2035-06-19

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001415889-25-017996 · form4-06232025_090657.xml · derivative · entry 1

STOVER JACK E · CIK 0001203603 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2035-06-19

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001415889-25-017995 · form4-06232025_090658.xml · derivative · entry 1

Shoemaker Mary Teresa · CIK 0001813552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2035-06-19

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001415889-25-017992 · form4-06232025_090600.xml · derivative · entry 1

CAUTREELS WERNER · CIK 0001237419 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2035-06-19

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001104659-25-033149 · tm2511901-1_4seq1.xml · derivative · entry 2

TPAV, LLC · CIK 0002017798 · 10% owner

Savchuk Nikolay · CIK 0002017800 · Chief Operating Officer · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 905,497 shares

Expires not disclosed

F4 · derivative.exercise_price: Each share of Series C Preferred Stock is convertible into 400 shares of the Issuer's common stock, subject to an issuance limitation that prohibits the holder from converting such shares of Series C Preferred Stock to the extent that, after giving effect to the issuance of shares of common stock after such conversion, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates) would beneficially own in excess of 19.99% of the shares of common stock of the Issuer then outstanding (the "Beneficial Ownership Limitation").

F1 · kind: On April 2, 2025, the TPAV, LLC ("TPAV") disposed of all of the shares of the Issuer's Common Stock and Series C Non-Voting Convertible Preferred Stock ("Series C Preferred Stock") held by TPAV as of such date through a pro rata distribution of such shares to its members, including Nikolay Savchuk. No consideration was paid in connection with such distribution. As a result of the distribution, TPAV is no longer a 10% owner, and therefore is no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and will no longer report any such transactions on Form 4 or Form 5. Mr. Savchuk will continue to be subject to Section 16.

F1 · price: On April 2, 2025, the TPAV, LLC ("TPAV") disposed of all of the shares of the Issuer's Common Stock and Series C Non-Voting Convertible Preferred Stock ("Series C Preferred Stock") held by TPAV as of such date through a pro rata distribution of such shares to its members, including Nikolay Savchuk. No consideration was paid in connection with such distribution. As a result of the distribution, TPAV is no longer a 10% owner, and therefore is no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and will no longer report any such transactions on Form 4 or Form 5. Mr. Savchuk will continue to be subject to Section 16.

F5 · derivative.exercise_date: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of the Issuer's common stock, which was obtained on September 16, 2024, the shares of Series C Preferred are convertible into shares of common stock, subject to the Beneficial Ownership Limitation.

F6 · derivative.expiration_date: The Series C Preferred Stock do not expire.

F2 · derivative.underlying_shares: On September 16, 2024, the Issuer's Board of Directors approved a one-for-twenty-five reverse stock split, which was effective on September 20, 2024. All shares of the Issuer's common stock and all shares of the Issuer's Series C Preferred Stock ("Series C Preferred Stock") reported in this Form 4 are presented on an after-reverse stock split basis.

F3 · balance_after: Mr. Savchuk is the sole manager on the Board of Managers of TPAV and also owns a 31% interest in TPAV. As a result of the distribution discussed in footnote 1 hereof, Mr. Savchuk received 170,710 shares of common stock of the Issuer and 638.1904 shares of Series C Preferred Stock of the Issuer and now owns those shares directly.

SEC source: 0001104659-25-033149 · tm2511901-1_4seq1.xml · nonDerivative · entry 1

TPAV, LLC · CIK 0002017798 · 10% owner

Savchuk Nikolay · CIK 0002017800 · Chief Operating Officer · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: On April 2, 2025, the TPAV, LLC ("TPAV") disposed of all of the shares of the Issuer's Common Stock and Series C Non-Voting Convertible Preferred Stock ("Series C Preferred Stock") held by TPAV as of such date through a pro rata distribution of such shares to its members, including Nikolay Savchuk. No consideration was paid in connection with such distribution. As a result of the distribution, TPAV is no longer a 10% owner, and therefore is no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and will no longer report any such transactions on Form 4 or Form 5. Mr. Savchuk will continue to be subject to Section 16.

F2 · shares: On September 16, 2024, the Issuer's Board of Directors approved a one-for-twenty-five reverse stock split, which was effective on September 20, 2024. All shares of the Issuer's common stock and all shares of the Issuer's Series C Preferred Stock ("Series C Preferred Stock") reported in this Form 4 are presented on an after-reverse stock split basis.

F1 · price: On April 2, 2025, the TPAV, LLC ("TPAV") disposed of all of the shares of the Issuer's Common Stock and Series C Non-Voting Convertible Preferred Stock ("Series C Preferred Stock") held by TPAV as of such date through a pro rata distribution of such shares to its members, including Nikolay Savchuk. No consideration was paid in connection with such distribution. As a result of the distribution, TPAV is no longer a 10% owner, and therefore is no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and will no longer report any such transactions on Form 4 or Form 5. Mr. Savchuk will continue to be subject to Section 16.

F3 · balance_after: Mr. Savchuk is the sole manager on the Board of Managers of TPAV and also owns a 31% interest in TPAV. As a result of the distribution discussed in footnote 1 hereof, Mr. Savchuk received 170,710 shares of common stock of the Issuer and 638.1904 shares of Series C Preferred Stock of the Issuer and now owns those shares directly.

SEC source: 0001415889-25-004727 · form4-02192025_110231.xml · derivative · entry 2

CAUTREELS WERNER · CIK 0001237419 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 96,348 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The Pre-Funded Warrants became exercisable upon stockholder approval on February 17, 2025.

F3 · derivative.expiration_date: The Pre-Funded Warrants do not expire.

SEC source: 0001415889-25-004727 · form4-02192025_110231.xml · nonDerivative · entry 1

CAUTREELS WERNER · CIK 0001237419 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Common Stock was acquired by way of an exercise of Pre-Funded Warrants at an exercise price of $0.01 per Pre-Funded Warrant. The Pre-Funded warrants were acquired as part of Class B Units, with each Class B unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit.

SEC source: 0001104659-25-006409 · tm254427-4_4seq1.xml · derivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VIII LLC · CIK 0001845804 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 96,348

Underlying: Common Stock · 96,348 shares

Expires not disclosed

F3 · price: The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit.

F6 · derivative.exercise_date: The Series A Warrants shall become exercisable on June 30, 2025; provided however, that the Series A Warrants may not be exercised prior to the issuer's receipt of stockholder approval of the exercise of the Series A Warrants, in accordance with Nasdaq listing rules.

F7 · derivative.expiration_date: The Series A Warrants shall expire on the date that is the earlier of (a) December 31, 2029, and (b) subject to the fulfilment of certain equity conditions, thirty trading days after the last of the following data readouts to occur, as announced by the issuer: (i) Ferret animal model Bird Flu data, (ii) non-human primate Bird Flu data, or (iii) Phase 2a Influenza A human clinical data.

F4 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII.

F5 · ownership.nature: Each of OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including any of the reporting persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001104659-25-006409 · tm254427-4_4seq1.xml · derivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VIII LLC · CIK 0001845804 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 96,348

Underlying: Common Stock · 96,348 shares

Expires not disclosed

F3 · price: The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit.

F1 · derivative.exercise_date: The Pre-Funded Warrants shall become exercisable upon stockholder approval of the exercise of the Pre-Funded Warrants, in accordance with Nasdaq listing rules.

F2 · derivative.expiration_date: The Pre-Funded Warrants do not expire.

F4 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII.

F5 · ownership.nature: Each of OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including any of the reporting persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001104659-25-006408 · tm254427-3_4seq1.xml · derivative · entry 2

CAUTREELS WERNER · CIK 0001237419 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,348

Underlying: Common Stock · 96,348 shares

Expires not disclosed

F3 · price: The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit.

F4 · derivative.exercise_date: The Series A Warrants shall become exercisable on June 30, 2025; provided however, that the Series A Warrants may not be exercised prior to the issuer's receipt of stockholder approval of the exercise of the Series A Warrants, in accordance with Nasdaq listing rules.

F5 · derivative.expiration_date: The Series A Warrants shall expire on the date that is the earlier of (a) December 31, 2029, and (b) subject to the fulfilment of certain equity conditions, thirty trading days after the last of the following data readouts to occur, as announced by the issuer: (i) Ferret animal model Bird Flu data, (ii) non-human primate Bird Flu data, or (iii) Phase 2a Influenza A human clinical data.

SEC source: 0001104659-25-006408 · tm254427-3_4seq1.xml · derivative · entry 1

CAUTREELS WERNER · CIK 0001237419 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,348

Underlying: Common Stock · 96,348 shares

Expires not disclosed

F3 · price: The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit.

F1 · derivative.exercise_date: The Pre-Funded Warrants shall become exercisable upon stockholder approval of the exercise of the Pre-Funded Warrants, in accordance with Nasdaq listing rules.

F2 · derivative.expiration_date: The Pre-Funded Warrants do not expire.

SEC source: 0001104659-25-006407 · tm254427d2_4seq1.xml · derivative · entry 2

TPAV, LLC · CIK 0002017798 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,348

Underlying: Common Stock · 96,348 shares

Expires not disclosed

F3 · price: The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit.

F4 · derivative.exercise_date: The Series A Warrants shall become exercisable on June 30, 2025; provided however, that the Series A Warrants may not be exercised prior to the issuer's receipt of stockholder approval of the exercise of the Series A Warrants, in accordance with Nasdaq listing rules.

F5 · derivative.expiration_date: The Series A Warrants shall expire on the date that is the earlier of (a) December 31, 2029, and (b) subject to the fulfilment of certain equity conditions, thirty trading days after the last of the following data readouts to occur, as announced by the issuer: (i) Ferret animal model Bird Flu data, (ii) non-human primate Bird Flu data, or (iii) Phase 2a Influenza A human clinical data.

SEC source: 0001104659-25-006407 · tm254427d2_4seq1.xml · derivative · entry 1

TPAV, LLC · CIK 0002017798 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,348

Underlying: Common Stock · 96,348 shares

Expires not disclosed

F3 · price: The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit.

F1 · derivative.exercise_date: The Pre-Funded Warrants shall become exercisable upon stockholder approval of the exercise of the Pre-Funded Warrants, in accordance with Nasdaq listing rules.

F2 · derivative.expiration_date: The Pre-Funded Warrants do not expire.

SEC source: 0001104659-25-006406 · tm254427-1_4seq1.xml · derivative · entry 2

Savchuk Nikolay · CIK 0002017800 · Director · Chief Operating Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By TPAV, LLC

Disclosed balance after: 96,348

Underlying: Common Stock · 96,348 shares

Expires not disclosed

F3 · price: The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit.

F5 · derivative.exercise_date: The Series A Warrants shall become exercisable on June 30, 2025; provided however, that the Series A Warrants may not be exercised prior to the issuer's receipt of stockholder approval of the exercise of the Series A Warrants, in accordance with Nasdaq listing rules.

F6 · derivative.expiration_date: The Series A Warrants shall expire on the date that is the earlier of (a) December 31, 2029, and (b) subject to the fulfilment of certain equity conditions, thirty trading days after the last of the following data readouts to occur, as announced by the issuer: (i) Ferret animal model Bird Flu data, (ii) non-human primate Bird Flu data, or (iii) Phase 2a Influenza A human clinical data.

F4 · ownership.nature: The Pre-Funded Warrants and Series A Warrants are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-006406 · tm254427-1_4seq1.xml · derivative · entry 1

Savchuk Nikolay · CIK 0002017800 · Director · Chief Operating Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By TPAV, LLC

Disclosed balance after: 96,348

Underlying: Common Stock · 96,348 shares

Expires not disclosed

F3 · price: The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit.

F1 · derivative.exercise_date: The Pre-Funded Warrants shall become exercisable upon stockholder approval of the exercise of the Pre-Funded Warrants, in accordance with Nasdaq listing rules.

F2 · derivative.expiration_date: The Pre-Funded Warrants do not expire.

F4 · ownership.nature: The Pre-Funded Warrants and Series A Warrants are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0000929638-24-003160 · form4.xml · derivative · entry 1

Greenwood Luba · CIK 0001853815 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,000

Underlying: Common Stock · 164,000 shares

Expires 2034-09-16

F1 · derivative.exercise_date: These options vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.

SEC source: 0001415889-24-017636 · form4-06202024_080620.xml · derivative · entry 3

Guerin Mark Patrick · CIK 0001607714 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,500

Underlying: Common Stock · 5,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On June 10, 2022 the reporting person was granted 16,500 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary

F2 · derivative.expiration_date: On June 10, 2022 the reporting person was granted 16,500 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary

SEC source: 0001415889-24-017636 · form4-06202024_080620.xml · nonDerivative · entry 2

Guerin Mark Patrick · CIK 0001607714 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,255

SEC source: 0001415889-24-017636 · form4-06202024_080620.xml · nonDerivative · entry 1

Guerin Mark Patrick · CIK 0001607714 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,476

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000929638-24-001366 · form4.xml · nonDerivative · entry 1

Redfield Robert · CIK 0002018274 · Acting Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,500

F1 · price: Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into common stock of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc.), par value $0.01 per share, on a one-for-one basis.

SEC source: 0000929638-24-001364 · form4.xml · derivative · entry 3

Pauza Charles David · CIK 0002018150 · Chief Science Officer Virology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 503,227

Underlying: Common Stock · 503,227 shares

Expires 2033-10-31

F2 · price: On April 1, 2024, the Company acquired Trawsfynydd Therapeutics, Inc. ("Trawsfynydd") in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC, and Trawsfynydd (the "Merger"). Upon consummation of the Merger, all of the outstanding shares of common stock of Trawsfynydd were converted into shares of Common Stock on a 1:20.1291 basis pursuant to the terms of the Merger Agreement.

F4 · price: Received in the Merger in exchange for stock options to acquire 25,000 shares of Trawsfynydd common stock with an exercise price of $0.0001 per share.

SEC source: 0000929638-24-001364 · form4.xml · derivative · entry 2

Pauza Charles David · CIK 0002018150 · Chief Science Officer Virology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 333,136

Underlying: Common Stock · 333,136 shares

Expires 2033-10-31

F2 · price: On April 1, 2024, the Company acquired Trawsfynydd Therapeutics, Inc. ("Trawsfynydd") in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC, and Trawsfynydd (the "Merger"). Upon consummation of the Merger, all of the outstanding shares of common stock of Trawsfynydd were converted into shares of Common Stock on a 1:20.1291 basis pursuant to the terms of the Merger Agreement.

F3 · price: Received in the Merger in exchange for stock options to acquire 16,550 shares of Trawsfynydd common stock with an exercise price of $1.38 per share.

SEC source: 0000929638-24-001364 · form4.xml · nonDerivative · entry 1

Pauza Charles David · CIK 0002018150 · Chief Science Officer Virology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,500

F1 · price: Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of common stock of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the "Company"), par value $0.01 per share ("Common Stock"), on a one-for-one basis.

SEC source: 0000929638-24-001362 · form4.xml · nonDerivative · entry 1

CAUTREELS WERNER · CIK 0001237419 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

F1 · price: Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into common stock of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc.), par value $0.01 per share, on a one-for-one basis.

SEC source: 0000929638-24-001360 · form4.xml · derivative · entry 8

Savchuk Nikolay · CIK 0002017800 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Viriom, Inc.

Disclosed balance after: 4,801.1144

Underlying: Common Stock · 48,011,144 shares

Expires not disclosed

F6 · derivative.exercise_price: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F4 · shares: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F6 · price: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F6 · derivative.exercise_date: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F6 · derivative.expiration_date: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F4 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000929638-24-001360 · form4.xml · derivative · entry 7

Savchuk Nikolay · CIK 0002017800 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By TPAV, LLC

Disclosed balance after: 2,584.3663

Underlying: Common Stock · 25,843,663 shares

Expires not disclosed

F6 · derivative.exercise_price: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F3 · shares: The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F6 · price: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F6 · derivative.exercise_date: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F6 · derivative.expiration_date: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F3 · balance_after: The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0000929638-24-001360 · form4.xml · derivative · entry 6

Savchuk Nikolay · CIK 0002017800 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 194.6223

Underlying: Common Stock · 1,946,223 shares

Expires not disclosed

F6 · derivative.exercise_price: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F6 · price: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F6 · derivative.exercise_date: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F6 · derivative.expiration_date: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

SEC source: 0000929638-24-001360 · form4.xml · derivative · entry 5

Savchuk Nikolay · CIK 0002017800 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,802,890

Underlying: Common Stock · 3,802,890 shares

Expires 2033-10-31

F5 · price: Received in the Merger in exchange for stock options to acquire 188,925 shares of Trawsfynydd common stock with an exercise price of $1.38 per share.

SEC source: 0000929638-24-001360 · form4.xml · nonDerivative · entry 4

Savchuk Nikolay · CIK 0002017800 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Viriom, Inc.

Disclosed balance after: 1,645,100

F4 · shares: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F1 · price: Received in exchange for shares of common stock of Trawsfynydd Therapeutics, Inc. ("Trawsfynydd") in connection with the acquisition (the "Merger") by Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the "Company") of Trawsfynydd in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC and Trawsfynydd. Upon consummation of the Merger, all of the outstanding shares Trawsfynydd common stock were converted into shares of common stock of the Company, par value $0.01 per share ("Common Stock"), on a 1:20.1291 basis pursuant to the terms of the Merger Agreement.

F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F4 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000929638-24-001360 · form4.xml · nonDerivative · entry 3

Savchuk Nikolay · CIK 0002017800 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By TPAV, LLC

Disclosed balance after: 885,532

F3 · shares: The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F1 · price: Received in exchange for shares of common stock of Trawsfynydd Therapeutics, Inc. ("Trawsfynydd") in connection with the acquisition (the "Merger") by Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the "Company") of Trawsfynydd in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC and Trawsfynydd. Upon consummation of the Merger, all of the outstanding shares Trawsfynydd common stock were converted into shares of common stock of the Company, par value $0.01 per share ("Common Stock"), on a 1:20.1291 basis pursuant to the terms of the Merger Agreement.

F3 · balance_after: The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0000929638-24-001360 · form4.xml · nonDerivative · entry 2

Savchuk Nikolay · CIK 0002017800 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,187

F2 · price: Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of Common Stock on a one-for-one basis.

SEC source: 0000929638-24-001360 · form4.xml · nonDerivative · entry 1

Savchuk Nikolay · CIK 0002017800 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,687

F1 · price: Received in exchange for shares of common stock of Trawsfynydd Therapeutics, Inc. ("Trawsfynydd") in connection with the acquisition (the "Merger") by Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the "Company") of Trawsfynydd in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC and Trawsfynydd. Upon consummation of the Merger, all of the outstanding shares Trawsfynydd common stock were converted into shares of common stock of the Company, par value $0.01 per share ("Common Stock"), on a 1:20.1291 basis pursuant to the terms of the Merger Agreement.

SEC source: 0000929638-24-001358 · form4.xml · derivative · entry 6

Dukes Iain D. · CIK 0001681955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Indirect · By Viriom, Inc.

Disclosed balance after: 4,801.1144

Underlying: Common Stock · 48,011,144 shares

Expires not disclosed

F5 · derivative.exercise_price: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F3 · shares: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F5 · price: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F5 · derivative.exercise_date: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F5 · derivative.expiration_date: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F3 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000929638-24-001358 · form4.xml · derivative · entry 5

Dukes Iain D. · CIK 0001681955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 194.6223

Underlying: Common Stock · 1,946,223 shares

Expires not disclosed

F5 · derivative.exercise_price: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F5 · price: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F5 · derivative.exercise_date: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

F5 · derivative.expiration_date: Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.

SEC source: 0000929638-24-001358 · form4.xml · derivative · entry 4

Dukes Iain D. · CIK 0001681955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,802,890

Underlying: Common Stock · 3,802,890 shares

Expires 2033-10-31

F4 · price: Received in the Merger in exchange for stock options to acquire 188,925 shares of Trawsfynydd common stock with an exercise price of $1.38 per share.

SEC source: 0000929638-24-001358 · form4.xml · nonDerivative · entry 3

Dukes Iain D. · CIK 0001681955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Indirect · By Viriom, Inc.

Disclosed balance after: 1,645,100

F4 · shares: Received in the Merger in exchange for stock options to acquire 188,925 shares of Trawsfynydd common stock with an exercise price of $1.38 per share.

F1 · price: Received in exchange for shares of common stock of Trawsfynydd Therapeutics, Inc. ("Trawsfynydd") in connection with the acquisition (the "Merger") by Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the "Company") of Trawsfynydd in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC and Trawsfynydd. Upon consummation of the Merger, all of the outstanding shares Trawsfynydd common stock were converted into shares of common stock of the Company, par value $0.01 per share ("Common Stock"), on a 1:20.1291 basis pursuant to the terms of the Merger Agreement.

F3 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000929638-24-001358 · form4.xml · nonDerivative · entry 2

Dukes Iain D. · CIK 0001681955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,187

F2 · price: Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of Common Stock on a one-for-one basis.

SEC source: 0000929638-24-001358 · form4.xml · nonDerivative · entry 1

Dukes Iain D. · CIK 0001681955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,687

F1 · price: Received in exchange for shares of common stock of Trawsfynydd Therapeutics, Inc. ("Trawsfynydd") in connection with the acquisition (the "Merger") by Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the "Company") of Trawsfynydd in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC and Trawsfynydd. Upon consummation of the Merger, all of the outstanding shares Trawsfynydd common stock were converted into shares of common stock of the Company, par value $0.01 per share ("Common Stock"), on a 1:20.1291 basis pursuant to the terms of the Merger Agreement.

SEC source: 0000929638-24-002743 · form4.xml · nonDerivative · entry 1

Dukes Iain D. · CIK 0001681955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,187

F1 · shares: On April 3, 2024, the reporting person filed a Form 4 that inadvertently reported the number of shares of common stock (the "Common Stock") of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc.) underlying a grant of restricted stock units as 67,550 instead of 67,500. Nevertheless, the number of shares of Common Stock beneficially owned following the reported transaction was correctly reported in the original Form 4 as 134,187.

F2 · price: Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of Common Stock on a one-for-one basis.

SEC source: 0000929638-24-002742 · form4.xml · nonDerivative · entry 1

Savchuk Nikolay · CIK 0002017800 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,187

F1 · shares: On April 3, 2024, the reporting person filed a Form 4 that inadvertently reported the number of shares of common stock (the "Common Stock") of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc.) underlying a grant of restricted stock units as 67,550 instead of 67,500. Nevertheless, the number of shares of Common Stock beneficially owned following the reported transaction was correctly reported in the original Form 4 as 134,187.

F2 · price: Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of Common Stock on a one-for-one basis.

SEC source: 0001415889-24-008141 · form4-03152024_090321.xml · nonDerivative · entry 2

Fruchtman Steven M · CIK 0001631251 · Director · PRESIDENT, CHIEF EXECUTIVE OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,792

SEC source: 0001415889-24-008142 · form4-03152024_090303.xml · nonDerivative · entry 2

Guerin Mark Patrick · CIK 0001607714 · CFO AND COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,976

SEC source: 0001415889-24-008141 · form4-03152024_090321.xml · derivative · entry 3

Fruchtman Steven M · CIK 0001631251 · Director · PRESIDENT, CHIEF EXECUTIVE OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,222

Underlying: Common Stock · 23,111 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On March 13, 2023 the reporting person was granted 69,333 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.

F2 · derivative.expiration_date: On March 13, 2023 the reporting person was granted 69,333 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.

SEC source: 0001415889-24-008141 · form4-03152024_090321.xml · nonDerivative · entry 1

Fruchtman Steven M · CIK 0001631251 · Director · PRESIDENT, CHIEF EXECUTIVE OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,519

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.